Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telaprevir (609) 609
science & technology (373) 373
life sciences & biomedicine (367) 367
humans (333) 333
boceprevir (309) 309
hepatitis c (290) 290
hepatitis c virus (240) 240
hepatitis c, chronic - drug therapy (225) 225
antiviral agents - therapeutic use (220) 220
ribavirin (190) 190
gastroenterology & hepatology (170) 170
oligopeptides - therapeutic use (169) 169
drug therapy, combination (168) 168
male (164) 164
female (154) 154
middle aged (153) 153
hepacivirus - genetics (146) 146
ribavirin - therapeutic use (137) 137
treatment outcome (129) 129
protease inhibitors (128) 128
interferon (127) 127
interferon-alpha - therapeutic use (121) 121
genotype (118) 118
antiviral agents - adverse effects (116) 116
proline - analogs & derivatives (107) 107
adult (106) 106
hepacivirus - drug effects (104) 104
infectious diseases (104) 104
aged (97) 97
oligopeptides - adverse effects (96) 96
antiviral agents (95) 95
hepatitis c, chronic - virology (93) 93
polyethylene glycols - therapeutic use (93) 93
biological response modifiers (91) 91
chronic hepatitis c (91) 91
antiviral agents - administration & dosage (89) 89
hepatitis (86) 86
hepatitis c - drug therapy (81) 81
oligopeptides - administration & dosage (79) 79
proline - therapeutic use (78) 78
proteases (76) 76
pharmacology & pharmacy (74) 74
care and treatment (73) 73
health aspects (72) 72
drug therapy (71) 71
recombinant proteins - therapeutic use (70) 70
pegylated interferon (63) 63
hcv (62) 62
virology (58) 58
gastroenterology and hepatology (53) 53
ribavirin - administration & dosage (53) 53
genetic aspects (52) 52
biological and medical sciences (51) 51
medical sciences (51) 51
protease inhibitors - therapeutic use (51) 51
viral hepatitis (51) 51
simeprevir (49) 49
hiv (48) 48
analysis (45) 45
drug interactions (45) 45
viral diseases (45) 45
human viral diseases (44) 44
interferon-alpha - administration & dosage (44) 44
pharmacology. drug treatments (42) 42
rna, viral - blood (42) 42
virus diseases (42) 42
young adult (42) 42
ribavirin - adverse effects (41) 41
viral load (41) 41
medicine & public health (40) 40
liver cirrhosis (39) 39
sofosbuvir (39) 39
cirrhosis (37) 37
hepatology (37) 37
anemia (36) 36
liver (36) 36
polyethylene glycols - administration & dosage (36) 36
hepatitis c, chronic - genetics (34) 34
interferon-alpha - adverse effects (34) 34
hepatitis c - virology (33) 33
liver transplantation (33) 33
protease inhibitor (33) 33
time factors (33) 33
antibiotics. antiinfectious agents. antiparasitic agents (32) 32
drug therapy, combination - methods (32) 32
hepatitis c, chronic - complications (32) 32
peginterferon (32) 32
proline - administration & dosage (32) 32
antiviral therapy (31) 31
clinical trials as topic (31) 31
recombinant proteins - administration & dosage (31) 31
general & internal medicine (30) 30
medicine, general & internal (30) 30
prospective studies (30) 30
interleukins - genetics (29) 29
retrospective studies (29) 29
antiviral agents - pharmacology (28) 28
proline - adverse effects (28) 28
sustained virological response (28) 28
hepacivirus - isolation & purification (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (542) 542
Spanish (28) 28
Japanese (19) 19
German (15) 15
Hungarian (12) 12
Portuguese (10) 10
French (7) 7
Russian (7) 7
Czech (5) 5
Chinese (3) 3
Turkish (3) 3
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
by Tutik Sri Wahyuni and Humairoh Mahfud and Adita Ayu Permatasari and Aty Widyawaruyanti and Achmad Fuad
Journal of basic and clinical physiology and pharmacology, ISSN 0792-6855, 11/2019, Volume 30, Issue 6
Herbal medicine | Hepatitis | Cytotoxicity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text EDITORIAL COMMENTARY: Does HIV Remain a Risk Factor for Achieving Sustained Virologic Response Under Direct Acting Antiviral–Based Modern Hepatitis C Virus Therapy?
by Jürgen Kurt Rockstroh
Clinical infectious diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
HIV/AIDS | HIV | interferon | DAA | telaprevir | hepatitis C
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
by Hézode, Christophe and Fontaine, Hélène and Dorival, Céline and Larrey, Dominique and Zoulim, Fabien and Canva, Valérie and de Ledinghen, Victor and Poynard, Thierry and Samuel, Didier and Bourlière, Marc and Zarski, Jean-Pierre and Raabe, Jean-Jacques and Alric, Laurent and Marcellin, Patrick and Riachi, Ghassan and Bernard, Pierre-Henri and Loustaud-Ratti, Véronique and Métivier, Sophie and Tran, Albert and Serfaty, Lawrence and Abergel, Armand and Causse, Xavier and Di Martino, Vincent and Guyader, Dominique and Lucidarme, Damien and Grando-Lemaire, Véronique and Hillon, Patrick and Feray, Cyrille and Dao, Thong and Cacoub, Patrice and Rosa, Isabelle and Attali, Pierre and Petrov-Sanchez, Ventzislava and Barthe, Yoann and Pawlotsky, Jean-Michel and Pol, Stanislas and Carrat, Fabrice and Bronowicki, Jean-Pierre and CUPIC Study Group and CUPIC Study Grp
Journal of hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Gastroenterology and Hepatology | Cirrhosis | Boceprevir | Chronic hepatitis C | Treatment | Telaprevir | Safety | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Oligopeptides - adverse effects | Serine Proteinase Inhibitors - adverse effects | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | France | Proline - administration & dosage | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Serine Proteinase Inhibitors - administration & dosage | Proline - analogs & derivatives | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Proline - adverse effects | Aged | Interferon-alpha - adverse effects | Oligopeptides - administration & dosage | Viral Load - drug effects | Cohort Studies | Care and treatment | Hepatitis C virus | Liver cirrhosis | Analysis | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
by Coilly, Audrey and Roche, Bruno and Dumortier, Jérôme and Leroy, Vincent and Botta-Fridlund, Danielle and Radenne, Sylvie and Pageaux, Georges-Philippe and Si-Ahmed, Si-Nafaa and Guillaud, Olivier and Antonini, Teresa Maria and Haïm-Boukobza, Stéphanie and Roque-Afonso, Anne-Marie and Samuel, Didier and Duclos-Vallée, Jean-Charles
Journal of hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 1, pp. 78 - 86
Gastroenterology and Hepatology | Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Liver Transplantation | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - drug therapy | Protease Inhibitors - adverse effects | Adult | Female | Aged | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Cohort Studies | Antiviral agents | Proteases | Liver | Transplantation | Hepatitis C virus | Hepatitis C | Anti-HIV agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
by Jacobson, Ira M and McHutchison, John G and Dusheiko, Geoffrey and Di Bisceglie, Adrian M and Reddy, K. Rajender and Bzowej, Natalie H and Marcellin, Patrick and Muir, Andrew J and Ferenci, Peter and Flisiak, Robert and George, Jacob and George, Shelley and Rizzetto, Mario and Shouval, Daniel and Sola, Ricard and Terg, Ruben A and Yoshida, Eric M and Adda, Nathalie and Bengtsson, Leif and Sankoh, Abdul J and Kieffer, Tara L and Kauffman, Robert S and M.D, Stefan Zeuzem and ADVANCE Study Team
The New England journal of medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and safety of telaprevir with pegylated interferon α‐2a and ribavirin in Japanese patients
by Kumada, Hiromitsu and Suzuki, Fumitaka and Kamiya, Naohiro and Orihashi, Madori and Nakayasu, Yoshiyuki and Yamada, Ichimaro
Hepatology research, ISSN 1386-6346, 05/2017, Volume 47, Issue 6, pp. 514 - 521
hepatology | ribavirin | peginterferon α‐2a | telaprevir | Japan | Telaprevir | Peginterferon α-2a | Hepatology | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Telaprevir for Retreatment of HCV Infection
by Zeuzem, Stefan and Andreone, Pietro and Pol, Stanislas and Lawitz, Eric and Diago, Moises and Roberts, Stuart and Focaccia, Roberto and Younossi, Zobair and Foster, Graham R and Horban, Andrzej and Ferenci, Peter and Nevens, Frederik and Müllhaupt, Beat and Pockros, Paul and Terg, Ruben and Shouval, Daniel and van Hoek, Bart and Weiland, Ola and Van Heeswijk, Rolf and De Meyer, Sandra and Luo, Don and Boogaerts, Griet and Polo, Ramon and Picchio, Gaston and Beumont, Maria and REALIZE Study Team
The New England journal of medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recurrence | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Retreatment | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2a | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Liver diseases | Cytokines | Leukopenia | Anemia | Infections | Ribonucleic acid--RNA | Ribavirin | Manuscripts | Genotype & phenotype | Consent | Interferon | Drug dosages | Genotypes | Neutropenia | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience
by Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri Giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina Barbara Guerrera Roberto Gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella Guido Piai Antonio Picardi Paola Pierri Grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra Gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone
World journal of hepatology, ISSN 1948-5182, 2016, Volume 8, Issue 22, pp. 949 - 956
Boceprevir;Telaprevir;Chronic | therapy;Peg-interferon;Ribavirin | hepatitis;Antiviral | Antiviral therapy | Boceprevir | Telaprevir | Chronic hepatitis | Peg-interferon | Ribavirin | Observational Study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
by Hézode, Christophe and Fontaine, Helene and Dorival, Celine and Zoulim, Fabien and Larrey, Dominique and Canva, Valerie and De Ledinghen, Victor and Poynard, Thierry and Samuel, Didier and Bourliere, Marc and Alric, Laurent and Raabe, Jean–Jacques and Zarski, Jean–Pierre and Marcellin, Patrick and Riachi, Ghassan and Bernard, Pierre–Henri and Loustaud–Ratti, Veronique and Chazouilleres, Olivier and Abergel, Armand and Guyader, Dominique and Metivier, Sophie and Tran, Albert and Di Martino, Vincent and Causse, Xavier and Dao, Thong and Lucidarme, Damien and Portal, Isabelle and Cacoub, Patrice and Gournay, Jerome and Grando–Lemaire, Veronique and Hillon, Patrick and Attali, Pierre and Fontanges, Thierry and Rosa, Isabelle and Petrov–Sanchez, Ventzislava and Barthe, Yoann and Pawlotsky, Jean–Michel and Pol, Stanislas and Carrat, Fabrice and Bronowicki, Jean–Pierre and CUPIC Study Group and CUPIC Study Grp
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 1, pp. 132 - 142.e4
Gastroenterology and Hepatology | Triple Therapy | Chronic Hepatitis C | DAA | CUPIC | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Multivariate Analysis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Liver Cirrhosis - epidemiology | Treatment Failure | Aged, 80 and over | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Liver Cirrhosis - drug therapy | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Proline - therapeutic use | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Proline - adverse effects | Aged | Cohort Studies | Care and treatment | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Antiviral strategies in hepatitis C virus infection
by Sarrazin, Christoph and Hézode, Christophe and Zeuzem, Stefan and Pawlotsky, Jean-Michel
Journal of hepatology, ISSN 0168-8278, 2012, Volume 56, Issue 1, pp. S88 - S100
Gastroenterology and Hepatology | Direct acting antiviral drugs | Boceprevir | Telaprevir | Drug combinations | Hepatitis C virus | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | RNA Replicase - antagonists & inhibitors | Hepatitis C, Chronic - drug therapy | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Cyclophilins - antagonists & inhibitors | Proline - therapeutic use | Proline - adverse effects | Protease Inhibitors - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
by Kumada, Hiromitsu and Toyota, Joji and Okanoue, Takeshi and Chayama, Kazuaki and Tsubouchi, Hirohito and Hayashi, Norio
Journal of hepatology, ISSN 0168-8278, 2011, Volume 56, Issue 1, pp. 78 - 84
Gastroenterology and Hepatology | Sustained virological response | Chronic hepatitis C | Telaprevir | Peginterferon | Ribavirin | Genotypes | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Antiviral agents | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Prospective Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Young Adult | Ribavirin - administration & dosage | Adult | Female | RNA, Viral - metabolism | Drug Therapy, Combination | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Oligopeptides - administration & dosage | Cohort Studies | Genetic aspects | Interferon | Universities and colleges | Hepatitis C | Hepatitis C virus | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights